2009 and Licensing - Drug Discovery Digest

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

MAY 21, 2025

In 2007, Sadelain and Rivire treated their first patient with leukemia, and in 2009, published details on how they manufactured personalized CAR T cells to treat patients with aggressive leukemia. After their clinical results, their technology was licensed to Juno Therapeutics (later acquired by Bristol Myers Squibb.)

Therapies

Therapies FDA Approval Engineering Immune Response

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

The Pharma Data

JUNE 24, 2025

A Legacy of Collaborative Excellence The relationship between Bayer and Tsinghua University began in 2009 as part of a broader effort by Bayer to establish strong academic linkages in Asia’s rapidly advancing research landscape.

Pharma R&D

Pharma R&D Pharmaceutical Companies Pharmaceuticals Science

Gepirone

New Drug Approvals

JUNE 11, 2025

5] History Gepirone was developed by Bristol-Myers Squibb in 1986, [5] but was out-licensed to Fabre-Kramer in 1993. 5] It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2009. Schatzberg AF, Nemeroff CB (2009). PMID 37856644.

FDA

FDA FDA Approval Treatment Clinical Trials

Elacestrant

New Drug Approvals

MAY 9, 2025

2] [4] Pharmacology Pharmacodynamics Elacestrant is an antiestrogen that acts as an antagonist of estrogen receptors , specifically targeting the estrogen receptor alpha (ER), which is the biological target of endogenous estrogens like estradiol. [1] 1] [8] Pharmacokinetics Elacestrant has an oral bioavailability of approximately 10%. [1]

FDA

FDA Pharmacokinetics Therapies Treatment

Pharmaceutical Negotiations Decoded: Lessons from the Trenches

Drug Patent Watch

JANUARY 14, 2025

From mergers and acquisitions to licensing agreements and pricing discussions, these complex interactions demand a unique blend of scientific knowledge, business acumen, and interpersonal skills. Intellectual property is often a central issue in pharmaceutical negotiations, particularly in licensing deals and partnerships.

Pharmaceuticals

Pharmaceuticals Compliance Licensing Licensing

Unlocking the power of stem cell therapy

Drug Target Review

FEBRUARY 9, 2024

Dr Scheer earned his medical degree from New York Medical College and subsequently completed his Surgical internship at Mount Sinai Beth Israel, followed by training in neurological surgery at the Albert Einstein College of Medicine until 2009.

Therapies

Therapies Immune Response Clinical Trials Treatment

Peijia Medical and HighLife Enter Into License and Technology Transfer Agreement for Transeptal Mitral Valve Replacement in Greater China

The Pharma Data

DECEMBER 20, 2020

” Under the License Agreement, Peijia and HighLife will establish a joint review committee to enhance a mutual sharing of information about the development as well as commercialization of the TMVR products, further deepening cooperation between the two companies. SUZHOU, China and PARIS , Dec.

Licensing

Licensing Licensing Production Treatment

FDA Knows Its Own Strength—and It Includes Concentration

FDA Law Blog: Biosimilars

FEBRUARY 26, 2024

This of course, make sense—after decades of experience implementing the Hatch-Waxman, Congress and FDA had learned a few new tricks by 2009/2010. To Boehringer’s first and most significant argument, that Congress intended the terms “strength” to match FDA’s interpretation in 2009—prior to the codification of the definition in 21 C.F.R.

FDA

FDA Biosimilars Production Regulations

ViiV?Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool

The Pharma Data

MAY 27, 2022

ViiV Healthcare and MPP are actively negotiating voluntary licensing terms to help widen access to innovative HIV prevention measure . generic version of the product. About ViiV Healthcare.

Licensing

Licensing Licensing Treatment Production

Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations

The Pharma Data

OCTOBER 6, 2021

It is also licensed under the brand name Efluelda ® in Europe where it is indicated for adults aged 60 and older. It is also licensed under the brand name Efluelda® in Europe where it is indicated for adults aged 60 and older.

Vaccine

Vaccine Licensing Licensing Immune Response

Coronavirus: Health workers' army to be trained to deliver Covid vaccine

The Pharma Data

AUGUST 28, 2020

The UK remains under the jurisdiction of the European Medicines Agency and its licensing scheme until the end of the Brexit transition period on 31 December 2020. A rapidly-developed vaccine for H1N1 swine flu in 2009, Pandemrix, was linked to a small number of people developing chronic sleep disorder narcolepsy. Source link.

Vaccine

Vaccine Immune Response Nurses Government

Acoltremon

New Drug Approvals

JUNE 26, 2025

Kühn FJ, Kühn C, Lückhoff A (February 2009). . “Menthol derivative WS-12 selectively activates transient receptor potential melastatin-8 (TRPM8) ion channels” Pakistan Journal of Pharmaceutical Sciences. 21 (4): 370–378. PMID 18930858. 284 (7): 4102–4111. doi : 10.1074/jbc.M806651200.

FDA

FDA Clinical Trials Small Molecule FDA Approval

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

FEBRUARY 28, 2024

Previously, Mr Ho served as a Senior Equity Research Analyst at Bank of America from 2006 to 2009 and an Equity Research Analyst at Piper Jaffray & Co. Normality sensing licenses local T cells for innate-like tissue surveillance. from 2003 to 2006, covering the biotechnology and life-science tools sectors.

Therapies

Therapies Engineering Molecular Biology Science

Separating the Hype from the Hyperbole Surrounding FDORA’s Alternatives to Animal Testing under the FD&C Act

FDA Law Blog: Drug Discovery

FEBRUARY 2, 2023

For more on FDORA’s other provisions, see HPM’s complete summary here ). Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. 42 U.S.C. § 262(k)(2)(A)(i)(I).

Animal Testing

Animal Testing Biosimilars Cell Based Assays Clinical Trials

Palovarotene

New Drug Approvals

AUGUST 21, 2023

4] [5] History Palovarotene is a retinoic acid receptor gamma (RARγ) agonist licensed to Clementia Pharmaceuticals from Roche Pharmaceuticals. 22 October 2009. Hind M, Stinchcombe S (November 2009). 4] [5] It is a highly selective retinoic acid receptor gamma (RARγ) agonist. [6] 22] Ipsen acquired Clementia in 2019. [23]

FDA

FDA Clinical Trials Treatment Pharmaceuticals

Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly’s Pivotal Phase 3 Studies

The Pharma Data

MARCH 27, 2022

OLUMIANT, a once-daily, oral JAK inhibitor was discovered by Incyte and licensed to Lilly. In December 2009, Lilly and Incyte announced an exclusive worldwide license and collaboration agreement for the development and commercialization of OLUMIANT and certain follow-on compounds for patients with inflammatory and autoimmune diseases.

Licensing

Licensing Licensing Disease FDA Approval

Accelerated Approval and Confirmatory Trials: Timing is Everything

The Premier Consulting Blog

OCTOBER 21, 2024

While requiring confirmatory trials at the time of accelerated approval is not new, earlier cases like Folotyn® (2009) and Beleodaq® (2014) demonstrate how the FDA has, in the past, mandated full enrollment in such trials before approval.

Trials

Trials FDA Clinical Trials Disease

Advanced Bionics Receives FDA Approval for Marvel Cochlear Implant Platform and World’s First Sound Processor for Children

The Pharma Data

DECEMBER 9, 2020

Founded in 1993 and a subsidiary of the Sonova Group since 2009, AB develops cutting-edge cochlear implant technology that allows recipients to hear their best. and any use of such marks by Sonova AG is under license. AB joined Phonak as part of the Sonova Group of companies and began a collaboration unlike any other in the industry.

FDA Approval

FDA Approval FDA Production Licensing

DARPA Neurotechnology: The Deep Dive

Codon

MARCH 28, 2023

In 2009, the USC professor received millions from the Defense Advanced Research Projects Agency, or DARPA, to build a device that plugs into the brain and enhances memory recall. The first project, REMIND, began in 2009. View our database of DARPA neurotechnology projects online. “I am a brain, Watson.

Engineering

Engineering Research Science FDA Approval

Analysis Life Sciences Thank You FDA’s new guidance on postapproval manufacturing changes for biosimilars focuses on current practice, new dosage forms

Agency IQ

JULY 26, 2024

BY LAURA DIANGELO, MPH , RACHEL COE, MSC | JUL 23, 2024 9:54 PM CDT Biosimilarity and interchangeability: A quick recap The Biologics Price Competition and Innovation (BPCI) Act of 2009 intended to increase the number of biologic products on the market by creating two types of approvals for biosimilar products.

Biosimilars

Biosimilars Science FDA Production

Home – Beat Kidney Disease – 2020 – Beat Kidney Disease

The Pharma Data

MAY 14, 2021

Description: Copyright © 2009 – 2021 BeatKidneyDisease.com All Rights Reserved. If within the first 60 days of receipt you are not satisfied with Wake Up Lean , you can request a refund by sending an email to the address given inside the product and we will immediately refund your entire purchase price, with no questions asked.

Disease

Disease Production Licensing Licensing

ATUZAGINSTAT

New Drug Approvals

SEPTEMBER 29, 2024

In August 2022, Cortexyme discontinued the gingipain inhibitor program, and offered it for external licensing ( press release ). 2009 Mar;77(3):1246-61. Known as gingipains, these proteases penetrate gingival tissue and cause inflammation at the site of periodontitis ( O’Brien-Simpson et al., Infect Immun.

Small Molecule

Small Molecule DNA Disease Trials

Decades Later, Congress Continues Debating the Preserve Access to Affordable Generics (and Biosimilars) Act; But will the Recent Jarkesy SCOTUS Decision Finally Put an End to the Insanity?

FDA Law Blog: Biosimilars

AUGUST 29, 2024

3582 —well before the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”) established the biosimilar biological product licensure pathway, and years before the U.S. Supreme Court declined to hold, in FTC v. Actavis, Inc. , 2233 (2013) , that so-called reverse payment settlement agreements are presumptively unlawful.

Analysis Life Sciences Thank You The 51 regulations that FDA is currently working on

Agency IQ

JUNE 16, 2023

0910-AI26 September 2023 March 2023 Final Rule Stage Biologics License Applications and Master Files The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) deemed any biological product approved in a new drug application (NDA) to be a biologics license application (BLA) on March 23, 2020.

Regulations

Regulations FDA Science Production

OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis

The Pharma Data

NOVEMBER 9, 2021

In December 2009, Lilly and Incyte blazoned an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib and certain follow-on composites for cases with seditious and autoimmune conditions.

Treatment

Treatment FDA Approval Licensing Licensing

HIV prevention and treatment, alongside pipeline advances at CROI 2021

The Pharma Data

MARCH 2, 2021

and Shionogi Limited as shareholders, today announced the presentation of 16 sponsored abstracts from its diverse portfolio of innovative pipeline and licensed HIV treatment and prevention options at the Conference on Retroviruses and Opportunistic Infections (CROI 2021), being held virtually 6-10 March. About ViiV Healthcare.

Treatment

Treatment Pharmacokinetics Licensing Licensing

Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus

The Pharma Data

AUGUST 1, 2021

Financial considerations AstraZeneca acquired global rights to Saphnelo through an exclusive license and collaboration agreement with Medarex, Inc. The option for Medarex to co-promote the product expired on its acquisition by Bristol-Myers Squibb (BMS) in 2009.

Trials

Trials Therapies Disease Treatment

Article FDA Thank You Vaccines advisory panel endorses move to trivalent formulation for U.S. flu vaccines

Agency IQ

MARCH 7, 2024

Influenza strains are named according to the HA and NA subtypes (at least 18 HA and 11 NA subtypes have been identified), as with the H1N1 influenza strain that famously wreaked havoc in 2009. That influenza A virus strain is now termed A(H1N1)pdm09, to signify the pandemic of 2009.

Vaccine

Vaccine FDA Virus Licensing

Janssen Submits Application Seeking U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis

The Pharma Data

OCTOBER 9, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Application utilizes extrapolation-based strategy across existing breadth of STELARA data in patients living with this chronic inflammatory disease.

Treatment

Treatment FDA Approval FDA Pharmaceutical Companies

Treatment Plans That Worked

The Pharma Data

MAY 13, 2021

The Executive Director of the Institute for Behavior Change (IBC), licensed psychologist and certified school psychologist Steve Kossor, has been involved in the planning and delivery of what became known as Intensive Behavioral Health Services (IBHS) in Pennsylvania since 1981. push(arguments)},i[r].l=1*new PA Senate honors IBC Founder.

Treatment

Treatment Production Licensing Licensing

Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

The Pharma Data

APRIL 8, 2021

Baricitinib, an oral JAK inhibitor, was discovered by Incyte and licensed to Lilly. In December 2009, Lilly and Incyte announced an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib and certain follow-on compounds for patients with inflammatory and autoimmune diseases.

Hospitals

Hospitals FDA Approval Laboratories Treatment

Merkin Prize in Biomedical Technology awarded to F. William Studier for development of widely used protein- and RNA-production platform

Broad Institute

MAY 14, 2024

“Today, virtually every protein you want to produce in bacteria is made with a T7 system,” said Venki Ramakrishnan of the MRC Laboratory of Molecular Biology in Cambridge, England, and a winner of the 2009 Nobel Prize in Chemistry. There’s not a single molecular biology or biochemistry lab I know that doesn’t use T7.” and around the world.

RNA

RNA Production Molecular Biology Laboratories

U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older

The Pharma Data

JUNE 18, 2021

Noninvasive Streptococcus pneumoniae Serotypes Recovered from Hospitalized Adult Patients in the United States in 2009 to 2012. Clin Infect Dis. 2016;62(9):1119-1125. 18 Mendes RE, Hollingsworth RC, Costello A, et al. Antimicrob Agents Chemother. 2015;59(9):5595-5601. 19 Olarte L, Barson WJ, Lin PL, et al.

Vaccine

Vaccine FDA Approval FDA Disease

Analysis Life Sciences Thank You Everything the FDA is planning to do in Q3 2023

Agency IQ

JULY 28, 2023

September 2023 Final Rule Stage Biologics License Applications and Master Files The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) deemed any biological product approved in a new drug application (NDA) to be a biologics license application (BLA) on March 23, 2020.

FDA

FDA Science Biosimilars Regulations

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

The Pharma Data

MAY 4, 2021

Long-acting cabotegravir has not been approved or licensed anywhere in the world for use in HIV prevention. . HIV continues to be a global public health crisis, with an estimated 38 million people living with HIV and 1.7 million new cases of HIV at the end of 2019. [3] For more information, visit [link].

FDA

FDA Trials Drugs Clinical Trials

Article FDA Thank You FDA unveils long-awaited Patient Medication Information proposed rule

Agency IQ

JUNE 2, 2023

In 2009, the agency held a workshop to discuss the gaps in existing frameworks and present some new options for discussion, including four “prototypes” of potential PMIs. However, only licensed blood establishments would be required to submit PMI to FDA for approval.”

FDA

FDA FDA Approval Production Regulations

Lilly accelerating baricitinib’s availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements | Eli Lilly and Company

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic. BA HCP ISI 09JUL2020.

Licensing

Licensing Licensing Therapies Laboratories

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries | Eli Lilly and Company

The Pharma Data

MAY 4, 2021

About OLUMIANT ® (baricitinib) OLUMIANT, a once-daily, oral JAK inhibitor was discovered by Incyte and licensed to Lilly. Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and the Institute of Microbiology , Chinese Academy of Science (IMCAS). It is approved in the U.S.

Therapies

Therapies Hospitals Treatment FDA Approval

Natural Penis Enlargement | The PE Bible

The Pharma Data

MAY 16, 2021

1: Increase in penis size data, and duration to achieve such growth has been collected from user feedback from 2009-2012. Don’t forget, I’m taking all the risk… If after trying my penis growth methods, you don’t get the same earth shattering results that I did, I’ll refund every penny. What have you got to lose?

Production

Production Testimonials Licensing Licensing

Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata

The Pharma Data

OCTOBER 29, 2020

Baricitinib, an oral JAK1/JAK2 inhibitor discovered by Incyte, is developed by Lilly under license from Incyte. For more information about the Lilly data being presented at this year’s virtual Fall Clinical Dermatology meeting, please visit [link].

Therapies

Therapies Treatment Disease Clinical Trials

New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis

The Pharma Data

APRIL 6, 2021

Ongoing research for baricitinib, an oral JAK inhibitor discovered by Incyte and licensed to Lilly, in adult and pediatric AD, alopecia areata (AA), systemic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA), COVID-19 and for its approved indication for rheumatoid arthritis (RA) continues.

Treatment

Treatment Drugs Clinical Trials Therapies

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

The Pharma Data

MARCH 4, 2021

” Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. In December 2009, Lilly and Incyte announced an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib and certain follow-on compounds for patients with inflammatory and autoimmune diseases.

Trials

Trials Treatment Therapies Clinical Trials

Analysis Chemical Thank You Highlights of the EPA’s Unified Agenda for Spring 2023

Agency IQ

JUNE 16, 2023

The AWIA, section 2009(a), also revises the scope of a consolidation plan under the Safe Drinking Water Act (SDWA), subsection 1414(h)(1), to include a contract for significant managerial or administrative functions of a PWS. This rule is the second of two rulemakings (Phase II) that EPA is undertaking to update its FOIA regulations.

Regulations

Regulations Compliance Production Science

Lilly and Incyte’s baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation

The Pharma Data

AUGUST 3, 2021

Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. OLUMIANT, a once-daily, oral JAK inhibitor was discovered by Incyte and licensed to Lilly. Authorized Use Under the EUA and Important Safety Information for baricitinib (in the United States) for COVID-19. BC HCP EUA ISI 28JUL2021.

Hospitals

Hospitals FDA Approval FDA Licensing

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

Trending Sources

Gepirone

Elacestrant

Pharmaceutical Negotiations Decoded: Lessons from the Trenches

Unlocking the power of stem cell therapy

Peijia Medical and HighLife Enter Into License and Technology Transfer Agreement for Transeptal Mitral Valve Replacement in Greater China

FDA Knows Its Own Strength—and It Includes Concentration

ViiV?Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool

Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations

Coronavirus: Health workers' army to be trained to deliver Covid vaccine

Acoltremon

Gamma delta T cells: a rising star in cancer therapy

Separating the Hype from the Hyperbole Surrounding FDORA’s Alternatives to Animal Testing under the FD&C Act

Palovarotene

Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly’s Pivotal Phase 3 Studies

Accelerated Approval and Confirmatory Trials: Timing is Everything

Advanced Bionics Receives FDA Approval for Marvel Cochlear Implant Platform and World’s First Sound Processor for Children

DARPA Neurotechnology: The Deep Dive

Analysis Life Sciences Thank You FDA’s new guidance on postapproval manufacturing changes for biosimilars focuses on current practice, new dosage forms

Home – Beat Kidney Disease – 2020 – Beat Kidney Disease

ATUZAGINSTAT

Decades Later, Congress Continues Debating the Preserve Access to Affordable Generics (and Biosimilars) Act; But will the Recent Jarkesy SCOTUS Decision Finally Put an End to the Insanity?

Analysis Life Sciences Thank You The 51 regulations that FDA is currently working on

OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis

HIV prevention and treatment, alongside pipeline advances at CROI 2021

Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus

Article FDA Thank You Vaccines advisory panel endorses move to trivalent formulation for U.S. flu vaccines

Janssen Submits Application Seeking U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis

Treatment Plans That Worked

Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

Merkin Prize in Biomedical Technology awarded to F. William Studier for development of widely used protein- and RNA-production platform

U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older

Analysis Life Sciences Thank You Everything the FDA is planning to do in Q3 2023

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

Article FDA Thank You FDA unveils long-awaited Patient Medication Information proposed rule

Lilly accelerating baricitinib’s availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements | Eli Lilly and Company

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries | Eli Lilly and Company

Natural Penis Enlargement | The PE Bible

Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata

New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Analysis Chemical Thank You Highlights of the EPA’s Unified Agenda for Spring 2023

Lilly and Incyte’s baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation

Stay Connected